Prime Medicine, Inc. (PRME)

NASDAQ: PRME · USD

$5.37

+1.02 (+23.4%)· Recorded snapshot

Market cap	955.3M
Revenue (ttm)	4.1M
Net income (ttm)	-187.9M
EPS (ttm)	-$1.09
Shares out	177.9M
Volume	14,611,788
Beta	2.38

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.1M
Net income (ttm): -187.9M
EPS (ttm): -$1.09
Market cap: 955.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-373.3

P25 n/aP50 n/aP75 n/a

ROIC-73.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PRME indicators

Market & fundamental data

Available fields

195

Groups with data

Currency

USD

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001894562
Company name	Prime Medicine, Inc.
Country	United States
Country code	US
CUSIP number	74168J101
Earnings date	2026-11-10
Earnings time	bmo
Employees	146
Employees change	-68
Employees growth	-31.78%
Enterprise value	$972.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2022-10-20
Is primary listing	Yes
Is SPAC	No
ISIN number	US74168J1016
Last 10-K release date	2026-03-03
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$955.3M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$5.37
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	PRME
U.S. state	Massachusetts
Website	https://primemedicine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.21%
EV/Sales	233.59x
FCF / EV yield	-16.49%
FCF yield	-16.79%
Forward EV/Sales	97.71x
Forward P/S	95.92x
P/B ratio	19.37x
P/S ratio	229.31x
Price / tangible book value	23.46x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-4,824.94%
Pretax margin	-4,613.11%
Profit per employee	$-1.3M
Revenue per employee	$27,897
ROA	-46.52%
ROA (5Y)	-37.39%
ROCE	-90.42%
ROE	-373.29%
ROE (5Y)	-107.37%
ROIC	-73.79%
SBC / revenue	657.28%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	9
EPS growth years	4
Net income growth quarters	2
Net income growth years	0
Revenue growth	-17.9%
Revenue growth (Q)	3.5%
Revenue growth (QoQ)	34.81%
Revenue growth 5Y	-4.8%
Revenue growth quarters	1
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-797,000
Depreciation and amortization	$7.4M
EBIT	$-196.5M
EBITDA	$-189.1M
EPS	$-1.09
FCF per share	$-0.88
Financing cash flow	$146.1M
Free cash flow	$-156.8M
Free cash flow minus SBC	$-183.6M
Gross profit	$-142.1M
Investing cash flow	$3.6M
Net cash flow	$-6.4M
Net income	$-187.9M
Operating cash flow minus SBC	$-182.8M
Operating income	$-196.5M
Revenue	$4.1M
Stock-based compensation	$26.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-5.87
Book value per share	$0.22
Debt / equity	2.83
Long-term assets	$152.2M
Long-term liabilities	$177.5M
Net cash (debt)	$-17.4M
Net cash / market cap	-1.86%
Net debt / equity	0.44
Piotroski F-Score	1
Property, plant and equipment	$137.5M
Shareholders' equity	$39.8M
Tangible book value	$39.8M
Tangible book value per share	$0.22
Total assets	$249M
Total cash	$95.1M
Total debt	$112.5M
Total liabilities	$209.2M
WACC	15.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.02
Current assets	$96.8M
Current liabilities	$31.7M
Current ratio	3.05
Net working capital	$-21M
Quick ratio	3
Working capital	$65.1M
Working capital turnover	0.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-36.42%
Dividend yield	0%
Shareholder yield	-36.42%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.37
1D price change	23.45%
1M price change	81.03%
1M total return	81.03%
1W price change	33.93%
1W total return	33.93%
1Y price change	1.94%
1Y return CAGR	1.94%
1Y total return	1.94%
20-day SMA	$3.67
200-day SMA	$3.49
3M price change	74.42%
3M total return	74.42%
3Y price change	-6.08%
3Y return CAGR	-2.07%
3Y total return	-6.08%
50-day SMA	$3.47
50-day SMA vs 200-day SMA	50under200
52-week high	$5.40
52-week high date	2026-10-28
52-week low	$2.67
52-week low date	2026-06-11
6M price change	43.05%
6M total return	43.05%
All-time high	$21.73
All-time high date	2022-11-14
All-time low	$1.11
All-time low date	2025-05-20
Average true range (ATR)	$0.41
Average volume	5.7M
Beta (1Y)	2.16
Beta (2Y)	2.83
Beta (5Y)	2.38
Change from 52-week high	-0.56%
Change from 52-week low	101.12%
Change from all-time high	-75.84%
Change from all-time low	372.97%
Change from open	27.86%
Day's gap	-3.45%
Dollar volume	$78.5M
High price	$5.43
Low price	$4.13
Monthly RSI	52.25
Open price	$4.20
Position in 52-week range	95.38%
Premarket change	-0.23%
Premarket close	$4.35
Premarket price	$4.34
Premarket volume	19.6K
Previous close	$4.35
Price vs 150-day SMA	55.74%
Price vs 20-day SMA	42.93%
Price vs 200-day SMA	50.6%
Price vs 50-day SMA	51.21%
Relative volume	2.54
Return from IPO open	-72.32%
Return from IPO price	-69.12%
RSI	72.33
Sharpe ratio	0.42
Sharpe ratio (3Y)	0.34
Sortino ratio	0.78
Sortino ratio (3Y)	0.61
Volume	14.6M
Weekly RSI	66.19
YTD price change	51.3%
YTD total return	51.3%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	112.2M
Float percentage	63.09%
Shares change (QoQ)	0.07%
Shares change (YoY)	36.42%
Shares held by insiders	14.52%
Shares held by institutions	53.72%
Shares outstanding	177.9M
Short % of float	29.28%
Short % of shares	18.48%
Short ratio	10 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	176

Deeper analysis on PRME

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PRME report

Is a complete PRME research report available?

No complete published report is available for Prime Medicine, Inc. (PRME) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Prime Medicine, Inc. (PRME)

Price

Financial snapshot

Fair-value bridge

Latest news · PRME

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PRME indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on PRME

Frequently asked questions